NeOnc Technologies (NTHI) announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company’s IP portfolio, covering its core pipeline, currently comprises 126 issued patents – 29 in the United States and 97 internationally; and 50 pending patents – 19 in the United States and 31 internationally. The Company’s IP protections span all major pharmaceutical markets, including the U.S., European Union, China, Japan, Brazil, and Australia, as the Company advances its portfolio of next-generation therapeutics toward regulatory approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01
- NeOnc Technologies Appoints New President Amid Strategic Moves
- NeOnc Technologies appoints Heshmatpour as President
- NeOnc Technologies announces NEO212 trial nears full enrollment
- Neonc Technologies Holdings Inc trading resumes